Table 1.

Recombinant vaccines derived from measles virus

Pathogen	Antigen	Positiona	Immunityb	Protection c	Reference
HBV	sHBsAg	P, H, L	ELISA, nAbs	n.t. (MV)	[10–12]
SIVmac	Env (+ Gag)	P	ELISA	n.t.	[13, 14]
MuV	HN, F	P	n.t.	n.t.	[14, 15]
WNV	E	P	nAbs, ELISpot	Yes	[16, 17]
HIV -1	Env	P	nAbs, ELISA, IFNγ-ICS	n.t.	[7, 18–24]
DENV	E, M; EDIII	P	ELISA, Cytokines	n.t.	[25–28]
SARS-CoV	S, N	P	ELISA, nAbs, ELISpot	Yes	[24, 29]
HPV	L1	P	ELISA, nAbs	n.t.	[30, 31]
HCV	C, E1, E2; E1/Ft, E2/Ft	P	ELISA, nAbs	n.t.	[32, 33]
Helicobacter pylori	NAP	N	ELISA, ELISpot	n.t.	[34]
RSV	F, G, M2-1, NP	N, P	ELISpot	Yes	[15, 35–37]
EBV	gB350	N, P	ELISpot	n.t.	[37]
MERS-CoV	S	H	ELISA, nAbs, ELISpot	Yes	[38]
NiV	G	N	ELISA	Yes	[39]
CHIKV	C-E3-E2-6k-E1	P	ELISA, nAbs, ELISpot	Yes	[8, 9]
JEV	prM-E	P	ELISA, nAbs	n.t.	[40]
FluV	HA	P	n.t.	n.t.	[15]

^aRelative genomic position of the ATU; N indicates first position in the genom, P and H indicate position of the ATU directly following P and H gene cassettes, respectively

^bTriggered antigen-specific immune responses after immunization determined by measuring total antibodies (ELISA), neutralizing antibodies (nAbs), or reactive T cells determined by ELISpot or intracellular cytokine staining (ICS)

^cProtective capacity of vaccine-induced immune responses after challenge of the appropriate animal model determined by reduction of pathogen load or attenuation of etiopathology